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Saudi ArabiaAbstract Diabetes mellitus substantially increases cardiovascular disease (CVD)
risk. Among Saudi Arabian citizens with diabetes, little is known about the preva-
lence and control of other CVD risk factors.
We extracted data from medical records of a random selection of 422 patients seen
between 2008 and 2012 at two diabetic clinics in Riyadh, Saudi Arabia. We calculated
the proportion of patients who had additional CVD risk factors: obesity (body mass
indexP 30 kg/m2), hypertension (BPP 140/90 mmHg), elevated cholesterol fractions,
andmultiple risk factors). Further, we calculated the proportion of patients meeting the
American Diabetes Associations recommended care targets for each risk factor.
Of 422 patients (mean age, 52 years), half were women, 56% were obese, 45% had
hypertension, and 77% had elevated LDL concentrations. In addition to diabetes, 70%
had two ormore CVD risk factors. Although 9%met both target HbA1c and BP values, only
3.5% had optimum HbA1c, BP, and lipid values.
In Saudi Arabias best diabetes clinics,most patients have poor control of their disease.
This huge disease burden and related care gaps have important health andfinancial impli-
cations for the country.
ª 2015 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Assiri),
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Since 2000, several studies have estimated the
prevalence of type-2 diabetes mellitus (DM) in
the Kingdom of Saudi Arabia (KSA) to be between
20% and 35% [10–12], the third highest in the world
[10]. Diabetes is the most costly medical disorder
in the KSA, consuming 23% of the healthcare expen-
ditures and 11% of all direct medical services [13].
One out of every five Saudi patients with diabetes
experiences nephropathy, which can lead to end-
stage renal disease. The per-patient cost for dialy-
sis in the KSA is $14,000 per year, with a total cost
of $540 million for the country for all diabetes-
related dialysis [14]. Additionally, the approximate
cost of managing one patient with an amputation
ranges between $40,000 and $75,000 per year
[15], and 4000 foot or leg amputations are per-
formed in KSA each year [1].
Patients with diabetes also have a higher risk of
cardiovascular disease (CVD) compared with
patients without diabetes [2]. Adjusting for age,
obesity, hypertension, dyslipidemia and tobacco
use, people with diabetes still have a fourfold
greater risk of experiencing a CVD event than do
people without diabetes [3,4]. Additionally, the
risk of a first myocardial infarction (MI) in patients
with diabetes is five times as high as that for non-
diabetics, and the risk for recurrent MI is twice that
of people with a history of MI who do not have dia-
betes [5]. Patients with diabetes also have an
increased risk of stroke [6].
In 2009, in the KSA, 2.7% of patients with dia-
betes also had CVD [11]. Awareness of the risks of
developing CVD is low among those with diabetes.
Risk factors for CVD (obesity, hypertension, dyslipi-
demia) are commonly observed in diabetes clinics,
but the actual proportion of diabetic patients with
these risk factors and how well they are being con-
trolled is unknown.
Several studies of patients with diabetes have
found that close control of glycemia and major
CVD risk factors, such as hypertension and dyslipi-
demia, substantially reduced CVD morbidity and
mortality [7,16–18]. The United Kingdom
Prospective Diabetes Study (UKPDS) reported that
a 1% reduction in HbA1c concentration decreased
micro- (e.g., retinopathy, nephropathy, neuropa-
thy) and long-term macro-vascular (e.g., coronary
events and strokes) diabetes-related complications
and mortality [19].
Given the high human and financial costs of dia-
betes and CVD, it is important to determine the
scope of the problem in the KSA. It was reasoned
that the patients most likely to have these riskfactors under control were those being treated at
diabetes clinics at leading major urban hospitals.
Accordingly, the present study was undertaken to
determine the proportion of diabetes patients at
two of these clinics who had other CVD risk factors
and how well their risk factors were controlled.
2. Methods
The study was approved by the Institutional Review
Boards of Emory University (Atlanta, USA) and King
Fahd Medical City (KFMC) (Riyadh, KSA). This study
involved collaboration with the KSAs Ministry of
Health (MoH).
2.1. Research questions
Three research questions were asked:
1) What are the proportions of patients with type-2
diabetes seen at two leading diabetes clinics in
Riyadh, KSA, between 2008 and 2012, who pre-
sented with other CVD risk factors?
2) What proportion of these patients was meeting the
American Diabetes Associations recommended
care targets for these CVD risk factors?
3) What protocols were associated with achieving
optimal control of CVD risk factors in these
patients?
The literature shows some variation in CVD risk
factors among men and women in the KSA; there-
fore, data were analyzed for men and women
separately.
2.2. Study population
Data were collected from medical records chosen
by a systematic random sampling of outpatients
treated at the diabetes clinics of KFMCs Diabetic
Center and Prince Salman Hospitals Al Sheikh
Diabetic Center. Patients were eligible if they
had a diagnosis of type-2 diabetes, were between
30 and 79 years old, were Saudi nationals, had no
previous history of CVD, and were not pregnant.
2.3. Sampling procedure
Records were systematically selected at each hos-
pital. At Prince Salman Hospital, patient data were
stored in a paper-based filing system. As such,
every third file on every shelf was selected. If the
patient was eligible for the study, the information
was abstracted from the record. If not, the record
was ignored and the next third file was taken.
At KFMC, patient data were stored electroni-
cally. A systematic random list of all patients with
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software program available at the hospital. The
above process of reviewing every third record for
inclusion or exclusion was used to select the files
of diabetes patients. Since KFMC has relatively bet-
ter medical records compared with most hospitals,
it was chosen as one of the hospitals to study.
However, since typically KFMC only sees Saudi
patients, the present study was restricted to
Saudi patients.
2.4. Measurements
For each patient, data were extracted based on
age, sex, height, weight, most recent blood pres-
sure measurement, and most recent serum concen-
trations of low-density lipoprotein (LDL), high-
density lipoprotein (HDL), total cholesterol,
triglycerides, and glycated hemoglobin (HbA1c).
Body mass index (BMI) was computed using height
and weight and reported in kg/m2. Thresholds
defining CVD risk factors are shown in Table 1. At
both hospitals, in order to best assess the current
status of control of CVD risk factors, the most
recent HgA1c value, lipid profile, and BP values
were used (available in the last three months). If
any of them were missing, that file was excluded.
2.5. Statistical methods
Descriptive statistics for continuous variables were
summarized using means and standard deviations,
and categorical data were reported as counts and
percentages. Outliers and influential or extreme
values were examined graphically with boxplots,
histograms, scatterplots, and quantitatively with
residual analyses. Demographic, clinical, and
metabolic features were compared between the
two hospitals using a Chi-Square test or Fisher
exact tests (when the sample size distributionsTable 1 Outcome variables in a study of the prevalence of ca
Arabia.
Outcomes
Low-density lipoproteina, mg/dL (mmol/L)
High-density lipoprotein, mena, mg/dL (mmol/L)
High-density lipoprotein, womena, mg/dL (mmol/L)
Total cholesterol, mg/dL (mmol/L)
Triglyceride, mg/dL (mmol/L)
Blood pressure, mmHg
Glycated hemoglobin (HbA1c), mg/dL (mmol/L)
Obesity/body mass index, kg/m2
a Adult Treatment Panel III guidelines [83].
b Optimal control of CVD risk factors among people with diabete
Standard of Care guidelines from 2013 [82].for categories of these variables were skewed or
small). Metabolic and clinical features of subjects
with hypertension were tested for an association
to assess whether they differed between the
hospitals.
3. Results
Data from 470 patients were extracted from the
medical records of the two clinics. After excluding
48 patients who did not meet the inclusion criteria
data, 422 patients met the criteria for inclusion.
The average age of patients was 52 years, and
half were women (n = 212). Mean age did not differ
between men and women (Table 2).
More than half the patients were obese
(BMIP 30 kg/m2), and almost half (45%) had
a diagnosis of hypertension (a systolic blood
pressureP 140 mmHg or a diastolic blood
pressureP 80 mmHg). The proportion of those
who had LDL concentrations greater than
3.4 mmol/L was 77% (Table 2). Many patients had
more than one risk factor, with most having two
to four (Table 4).
Among patients with complete data (n = 168),
only a minority met the target values of any CVD
risk factor except LDL (Table 4).
4. Discussion
Among 422 people with diabetes attending large
urban hospital clinics in Riyadh, KSA, 70% had two
or more CVD risk factors, and large proportions
were not controlling their risks.
With regard to poor control of CVD risk-factors,
the KSA is not alone in the Middle East. For exam-
ple, a retrospective United Arab Emirates (UAE)
study of 382 patients with diabetes found that
59% did not meet their targeted glycatedrdiovascular risk factors in patients with diabetes in Saudi
Elevated values Optimal valuesb
>130 (>3.4) <100 (<2.6)
<40 (<1.00) >40 (1.00)
<40 (<1.00) >50 (>1.3)
>200 (>5.172) <200 (<5.172)
P200 (P2.26) <150 (<1.7)
. . . <130/80
. . . 67.0%
P30 . . .
s were defined using the American Diabetic Association (ADA)
Table 2 Distribution of Cardiovascular Risk Factors in Saudi Arabian Patients with Diabetes, by Sex.
Risk factor Total sample, n = 422 Women, n = 212 Men, n = 210
Age, mean (SD), years 52.0 (10.26) 51.3 (9.49) 52.8 (10.95)
HbA1c mean (SD), % (n = 375) 9.00 (0.15) 9.22 (2.09) 8.76 (2.19)
HbA1c < 6.5% 43 (11.47) 19 (5.07) 24 (6.40)
HbA1cP 6.5% 332 (88.53) 177 (47.20 155 (41.33)
Body mass index, mean (SD), kg/m2 (n = 415) 31.67 (7.9) 33.95 (9.06) 29.37 (5.68)
Obesity (BMIP 30), n (%) 235 (56.63) 147 (35.42) 88 (21.20)
Hypertension, mean (SD) diastolic pressure,
mmHg (n=422)
77.15 (10.86) 75.62 (10.98) 78.69 (10.54)
Hypertension, mean (SD) systolic pressure,
mmHg (n = 422)
131.61 (18.25) 132.82 (19.23) 130.39 (17.15)
Hypertension diagnosis with and without
Systolic BPP 140 mmHg
and Diastolic BPP 80 mmHg, n (%)
190 (45.02) 109 (25.83) 81 (19.19)
Total cholesterol, mean (SD), mmol/L (n = 418) 4.65 (1.21) 4.65 (1.16) 4.65 (1.25)
Cholesterol > 5.18 mmol/L, n (%) 125 (29.90) 61 (14.59) 64 (15.31)
HDL, mean (SD), mmol/L (n = 373) 1.17 (0.41) 1.25 (0.44) 1.08 (0.36)
HDL < 1.0 mmol/L, n (%) 137 (36.73) 53 (14.21) 84 (22.52)
LDL, mean (SD), mmol/L (n = 363) 2.75 (0.94) 2.78 (0.9) 2.73 (0.99)
LDL > 3.4 mmol/L, n (%) 77 (21.21) 40 (11.02) 37 (10.19)
Triglyceride, mean (SD), mmol/L (n = 416) 1.74 (1.16) 1.6 (0.97) 1.9 (1.32)
TriglyceridesP 2.26 mmol/L, n (%) 86 (20.67) 35 (8.41) 51 (12.26)
Total cholesterol = <200 mg (or <5.172 mmol/L, LDL = >130 mg/dL (or >3.4 mmol/L), HDL = <40 mg/dL for both (or <1.00 mmol/L
for both), Triglyceride =P200 mg/dL (or P2.26 mmol/L).
32 F.Y. Al Slail et al.hemoglobin (HbA1C) values, 53% did not meet the
target values for systolic blood pressure, 27% did
not meet the target values for diastolic blood pres-
sure, and 28% did not meet the target values for
LDL concentrations [22,23]. In Lebanon, a
National Health Registry Study found that almost
half the participants had HbA1C concentrations
greater than 8%, and more than half had total
cholesterol concentrations of more than
5.0 mmol/L [24].
4.1. Cardiovascular disease risk factors
4.1.1. A1c concentrations
Most patients in this study had HbA1c concentra-
tions that were higher than 7% (mean, 9%; SD,
2.15%), well above the current ADA-recommended
goal of less than 7% to reduce CVD complications.
In a study over 8 years of subjects aged 45-79 in
Norfolk, United Kingdom, for every 1% increase in
HbA1c concentration, there was a 38% higher risk
of a macrovascular event, a 40% higher risk of a
microvascular event, and a 38% higher risk of death
[21]. Only 19% of patients with diabetes met the
ADA-recommended HbA1c concentration, a propor-
tion similar to the 21.8% found in a 2010 study of
1,188 patients in the Riyadh region [26]. Thus,
there is an urgent need to aggressively controlHbA1c concentrations and reduce them to under
7% while also considering individualized recom-
mendations for high-risk patients [25].
4.1.2. Hypertension
In this study, only 12% of 168 patients with com-
plete data had acceptable blood pressure measure-
ments (Table 4). This finding is much lower than
that in a 2010 study done at The King Fahd
National Guard Hospital, King Abdulaziz Medical
City, with participants in the same age group.
That study found that 39.0% of patients had optimal
control of their systolic blood pressure, and 40.6%
had optimal control of diastolic blood pressure
[26]. The UKPDS trial demonstrated that tight blood
pressure control compared with less tight control
resulted in 24% lower diabetes-related end points,
32% lower deaths related to diabetes, 44% in
strokes, and 37% lower in microvascular end points,
predominantly owing to a reduced risk of retinal
photocoagulation. After 9 years of follow-up, the
group assigned to tight blood pressure control also
had a 34% reduction in risk in the proportion of
patients with deterioration of retinopathy [55].
Reducing high blood pressure is important because
it increases fatal and nonfatal microvascular and
macrovascular complications, as well as the rela-
tive risk of fatal or nonfatal strokes [8].
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In the 168 patients with complete lipid data, 82%
had optimal concentrations for total cholesterol,
63% for triglyceride concentrations, 44% for HDL
concentrations, and 62% for LDL concentrations.
These results are slightly better than those of
another KSA study in which 55.5% of the partici-
pants had optimal LDL concentrations [26].
Participants in this study had a similar proportion
with optimal LDL concentrations as the partici-
pants in a 2005 United States study (62.2%) [27].
A 2006 Australian study also found that 60% of par-
ticipants had optimal LDL concentrations [28]. The
Cholesterol and Recurrent Events (CARE) trial and
the diabetic subset of the Scandinavian
Simvastatin Survival Study (4S) revealed a striking
decrease in CVD risk total mortality (0.57 [95% CI,
0.30 to 1.08; P = 0.09]) and major coronary heart
disease (CHD) events (0.45 [95% CI, 0.27 to 0.74;
P = 0.002]) when participants aimed for optimal
concentrations [9,20].
4.2. Multiple CVD risk factors
Almost half the patients in this study had more
than three CVD risk factors (Table 3). The associ-
ated morbidities of having multiple risk factors
are multiplicative rather than additive. It is imper-
ative that treatment and monitoring be instituted
to help prevent these morbidities [29,30]. This
group needs to be studied further; in particular,
it needs to be determined whether having multiple
risk factors varies by socioeconomic status. In a
2006 study, the combination of risk factors, such
as hypertension, smoking, high serum cholesterol,
and high blood glucose concentrations, accounted
for less than one third of CHD mortality, implyingTable 3 Frequency of multiple cardiovascular risk
factors among 232 Saudi Arabian Citizens with diabetes.
Risk factorsa per person, n n (%)
0 1 (0.43)
1 20 (8.6)
2 48 (20.7)
3 72 (31.0)
4 43 (18.5)
5 34 (14.7)
6 11 (4.7)
7 3 (1.3)
a Glycated hemoglobin, low-density lipoprotein, high-den-
sity lipoprotein, triglyceride, total cholesterol, blood pres-
sure, body mass index.that stress linked to low socioeconomic status is a
stronger predictor of mortality [31]. Similarly, a
study in the KSA showed that the proportion of
DM was higher in older people and among women,
widows, divorced persons, and the unemployed
[11].4.3. Control of risk factors
The present study found that 7.1% of diabetes
patients had optimal control of their HbA1c con-
centrations, blood pressure and LDL concentrations
(Table 4). In the KSA, a cross-sectional study of
1,107 participants of the same age group found
that 4.5% had optimal control of glucose and LDL
cholesterol concentrations and blood pressure
[32]. Only 3.6% of participants in this study had
optimal control of HbA1c and lipid (LDL, HDL,
triglyceride, and total cholesterol) concentrations
and blood pressure. This percentage would be
lower if obesity and smoking were included as addi-
tional risk factors. Accordingly, the factors associ-
ated with optimal and suboptimal control of
combined CVD risk factors need to be identified
and addressed.4.4. Barriers to controlling risk factors
The pronounced presence of multiple CVD risk fac-
tors among people with diabetes are the result of
structural deficiencies in healthcare, communica-
tion gaps between healthcare providers and
patients, and suboptimum adherence by patients
to preventive health behaviors.
A 2006 World Health Organization (WHO) report
indicated that in 2004, the KSA had 1.3 physicians
per 1,000 patients (ranking 77th among the coun-
tries surveyed), 0.22 pharmacists per 1000
patients (ranking 78th), and 3.0 nurses per 1000
patients (ranking 88th) [33]. Although the number
of these practitioners has risen in the past
10 years, there are not enough to take a full his-
tory, make complete examinations, or explain
results for each patient. Lack of multidisciplinary
care teams is an additional impediment. Under
these conditions, physicians find it difficult to
improve their clinical skills and to teach patients
behavioral strategies for controlling CVD risk fac-
tors [34].
Another barrier to providing optimal care is the
inability to track patient care and health out-
comes. Neither hospital in the study had a comput-
erized information system; both relied on paper
Table 4 Proportion of 232 Saudi patients with diabetes and optimal control of cardiovascular disease risk factors.
CVD risk factors under control n (%)
Glycated hemoglobin + blood pressure 15 (8.93)
Glycated hemoglobin + LDL 21 (12.50)
Glycated hemoglobin + blood pressure + LDL 12 (7.14)
Glycated hemoglobin + LDL + HDL + triglyceride + total cholesterol 10 (5.95)
Glycated hemoglobin + blood pressure + all lipids 6 (3.57)
Using the ADA guideline, HbA1c < 7, BP < 130/80, LDL < 100 mg/dL (or <2.6 mmol/L), HDLP 40 mg/dL (or 1.00 mmol/L)
for men, >50 mg/dL (or >1.3 mmol/L) for women, total cholesterol = <200 mg (or <5.172 mmol/L). Triglyceride 6 150 mg/dL
(or 1.7<mmol/L).
LDL, low-density lipoprotein; HDL, high-density lipoprotein; ALL lipids, LDL, HDL, triglyceride and total cholesterol.
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over time [35].
Cultural differences between health providers
and patients can also impinge risk-control efforts.
In 2010, only 21% of MoH physicians were Saudi
nationals and therefore may not be able to commu-
nicate effectively with Saudi patients [36].
In addition, poor reading skills and low health
literacy among patients are associated with a range
of adverse health outcomes and increased risk of
hospitalization and mortality. Thus, healthcare
providers need to be aware of the health literacy
levels of their patients. This information should
be documented clearly in the medical record so
that providers can attend to patients individual
needs [37].
Proper adherence to treatment also affects the
control of risk factors. Several studies show that
diabetes patients do not usually adhere to treat-
ment, which has been linked to increases in mor-
bidity, mortality and healthcare costs. Adherence
ranged from 62% to 64% in a review of the litera-
ture from 1966 through 2003; high adherence con-
tributes greatly to achieving optimal control over
multiple CVD risk factors. Adherence can be
improved with electronic patient monitoring sys-
tems. Improving adherence also requires identify-
ing patients who are not adhering to their
prescribed treatment. Then, those with poor gly-
cemic control resulting from poor adherence need
to be distinguished from those in whom poor con-
trol is caused by ineffective medication, and
finally, patients individual needs must be
addressed [36].4.5. Strengths and limitations of the study
Because of limited resources, the sample was smal-
ler than desirable. Data entry and collection byhospital staff may not have been completely accu-
rate, given the hospitals use of paper medical
records, but there is no reason to believe that
any inaccuracies were systematic and therefore a
source of bias. No differences in optimal diabetes
control were found between the tertiary and sec-
ondary hospitals studied, but the power of the
small sample was insufficient to detect important
differences. Another limitation is that duration
since diagnosis of diabetes was not abstracted for
this study. Such information is useful to determine
if there was sufficient time for control of risk factors
at the hospital for the patients. Quantification of
duration of diabetes would be useful in future
studies. In addition, quantifying cardiovascular
events in diabetic patients would be useful in
future investigations as well.
Although smoking is a great predictor of mortal-
ity and is possibly the single most preventable risk
factor for CHD, data on smoking status were not
routinely included in the medical records
reviewed. The relative risk for all-cause mortality
is twice as high among diabetic patients who smoke
than it is among those who do not [37]. The preva-
lence of smoking in the KSA is about 15% (including
cigarettes and shisha). A 2012 ban on smoking in
public and a ban on tobacco sales in Makkah and
Madinah have greatly reduced the incidence, but
without data on these patients, bias cannot be
ruled out.
This study pertains to hospital-based clinics and
cannot be completely generalized to primary
healthcare clinics where the severity of diabetes
is likely less. However, the level of expertise,
resources and monitoring in the primary healthcare
clinics are less than hospital-based clinics, and thus
there is reason to assume low levels of control of
CVD risk factors among diabetic patients in the pri-
mary healthcare clinics as well.
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